BioSpace News Archive

Ocugen, Inc. announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 6,750 shares of its common stock and restricted stock units covering an aggregate of 1,150 shares of common stock to one newly hired team member.

Breakthrough research has now revealed the true crystal forms of pharmaceutical psilocybin. A new study overcomes experimental challenges to solve the crystallographic puzzle and brings clarity to the unique crystalline arrangements, called polymorphs, that naturally arise from the production of synthetic psilocybin.

Deficiency of Vitamin D is a common issue faced by many across the globe. It is more common amongst the older adults.

Oral or mouth cancer usually occur on the surfaces of tongue, lips, cheek, gums, tonsils and salivary glands.

Fact.MR – A Market Research and Competitive Intelligence Provider: As per latest Fact.MR analysis, the global vocal biomarker market is anticipated to rise at a stellar CAGR of around 23.3% during the forecast period of 2018 and 2027.

Analgesics are also known as painkillers. As the name suggests, they are mainly used to lessen and treat pains and aches.

Everest Medicines (HKEX 1952.HK) and Providence Therapeutics (" Providence ") announced today that their COVID-19 vaccine, PTX-COVID19-B, has been recommended by an independent advisory group to be part of the WHO Solidarity Trial Vaccines (“STV”) clinical trial.

Provention Bio, Inc. today announced that the Company has appointed Christina Yi as Chief Operations Officer, responsible for manufacturing, supply chain and human resources, and Benedict Osorio as Chief Quality Officer, responsible for all aspects of quality.

Aptinyx to Host Virtual Portfolio Review Event on February 9th, 2022.

Galecto, Inc. (NASDAQ: GLTO), a publicly listed company focused on the development of novel treatments for fibrosis and cancer, today announced it has enrolled 10 of the anticipated 16 patients in its Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis.